Experimental antibodies aim to block cat allergy eye itch
NCT ID NCT07675811
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests whether two experimental antibodies, given alone or together, can reduce eye allergy symptoms caused by cat dander. About 570 adults and children aged 8 and older with confirmed cat allergy will receive either the antibodies or a placebo. The main goal is to see if the treatment reduces eye itching and redness after exposure to cat allergen.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
freneslerbart and mevonlerbart (alone or combined as REGN-2Cat)
What this could lead to
If successful, this could offer a new way to prevent or reduce eye allergy symptoms in people allergic to cats, without needing daily medication.
What could go wrong
This is still experimental. The treatment may not work better than placebo, and side effects are possible. It is not a cure for cat allergy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC CONJUNCTIVITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••